Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* lymphocyte predominant Hodgkin´s lymphoma (histologically proven)~* clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR \> 50mm/h)~* age 18 - 75~* WHO performance status 0-3~* normal organ function~* written informed consent~Exclusion Criteria:~* classical Hodgkin´s lymphoma~* composite lymphoma~* leucocytes \< 3000/µl~* thrombocytes \< 100.000/µl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).